Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile

  title={Characterization of Aclidinium Bromide, a Novel Inhaled Muscarinic Antagonist, with Long Duration of Action and a Favorable Pharmacological Profile},
  author={Amadeu Gavaldà and Montserrat Miralpeix and Israel Ramos and Raquel Otal and Cristina Carreño and Marisa Viñals and Teresa Doménech and Carla Carcasona and Blanca Reyes and Dolors Vilella and Jordi Gras and Julio Cortijo and Esteban Jes{\'u}s Morcillo and Jes{\'u}s Llenas and Hamish Ryder and Jorge Beleta},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={740 - 751}
Aclidinium bromide is a novel potent, long-acting inhaled muscarinic antagonist in development for the treatment of chronic obstructive pulmonary disease. Aclidinium showed subnanomolar affinity for the five human muscarinic receptors (M1–M5). [3H]Aclidinium dissociated slightly faster from M2 and M3 receptors than [3H]tiotropium but much more slowly than [3H]ipratropium. Its association rate for the M3 receptor was similar to [3H]ipratropium and 2.6 times faster than [3H]tiotropium. Residence… 

Tables from this paper

An update on the efficacy and safety of aclidinium bromide in patients with COPD

Clinical trials have provided evidence of sustained bronchodilation similar to that observed with tiotropium, and trial results have confirmed the positive safety profile of aclidinium, particularly in terms of a very low propensity to cause anticholinergic adverse events.

Aclidinium bromide, a new, long-acting, inhaled muscarinic antagonist: in vitro plasma inactivation and pharmacological activity of its main metabolites.

  • S. SentellasI. Ramos A. Gavaldà
  • Biology, Chemistry
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2010

Pharmacological Assessment of the In Vitro Functional Selectivity of Aclidinium Bromide at M3 and M2 Muscarinic Receptors in Human Tissue

Aclidinium exhibited kinetic selectivity for human bronchial versus atrial receptors, supporting a favorable cardiovascular safety profile and demonstrating competitive antagonism at M3 receptors with similar potency to comparators.

Pharmacological properties of revefenacin (TD‐4208), a novel, nebulized long‐acting, and lung selective muscarinic antagonist, at human recombinant muscarinic receptors and in rat, guinea pig, and human isolated airway tissues

Revefenacin is a potent, high affinity, and selective functional mAChR antagonist with kinetic selectivity for the hM3 receptor and produces potent and long‐lasting antagonism of mA cholinergic receptor‐mediated contractile responses in rat, guinea pig, and human airway tissue.

The potential for aclidinium bromide, a new anticholinergic, in the management of chronic obstructive pulmonary disease

The approved therapeutic dose of aclidinium 400 µg BID is an effective new treatment option for patients with COPD, and health status was significantly improved and dyspnea, nighttime and morning symptoms of COPD were likewise significantly reduced with aclIDinium.

In Vivo Pharmacological Characterization of TD-4208, a Novel Lung-Selective Inhaled Muscarinic Antagonist with Sustained Bronchoprotective Effect in Experimental Animal Models

The in vivo preclinical profile suggests that TD-4208 has the potential to be a long-acting bronchodilator for once-daily treatment of respiratory diseases and greater functional selectivity for the lung in preclinical models may translate to an improved tolerability profile compared with marketed muscarinic receptor antagonists.



Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea‐pig and human airways

Investigation of the duration of the bronchodilator action of the antimuscarinc drug glycopyrrolate compared to tiotropium and ipratropium found it to have a longer duration than that of ipRatropium, but less than those of tiottropium.

Effect of Ba 679 BR, a novel long-acting anticholinergic agent, on cholinergic neurotransmission in guinea pig and human airways.

The high potency, slow onset, and long duration of action of Ba 679 BR were also observed in human bronchi, suggesting that the drug may be a useful drug to provide convenient therapy for patients with obstructive airway disease.

Quantifying the association and dissociation rates of unlabelled antagonists at the muscarinic M3 receptor

It is demonstrated that a medium‐throughput competition kinetic binding assay can be used to determine accurate on and off rates of unlabelled compounds, providing the opportunity to optimise for kinetic parameters early in the drug discovery process.

Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping.

The results suggest that the slow dissociation profile of Ba 679 BR from human lung muscarinic receptors might be the underlying mechanism by which this drug achieves its long duration of action observed in functional tests.

Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on bronchial and cutaneous allergic responses to ascaris in dogs.

Findings suggest that Sm 857 may be useful for the treatment of bronchial asthma as an orally active drug, exerting its action probably through a mast cell stabilizing effect.

Discovery of novel quaternary ammonium derivatives of (3R)-quinuclidinol esters as potent and long-acting muscarinic antagonists with potential for minimal systemic exposure after inhaled administration: identification of (3R)-3-{[hydroxy(di-2-thienyl)acetyl]oxy}-1-(3-phenoxypropyl)-1-azoniabicyclo[

Aclidinium bromide is a potent muscarinic antagonist, with long duration of action in vivo, and was found to have a rapid hydrolysis in human plasma, minimizing the potential to induce class-related systemic side effects.

Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder

The evolving understanding of muscarinic receptor functions throughout the body is explored, with particular focus on the bladder, gastrointestinal tract, eye, heart, brain and salivary glands, and the implications for drugs used to treat OAB.

Effects of the new antiallergic drug 11-oxo-11H-pyrido[2,1-b] quinazoline-2-carboxylic acid on type I allergic reactions.

It may be concluded that Sm 857 exerts preferential effect on the respiratory system and that it might be useful in allergic asthma.

Synthesis and biological evaluation of new antimuscarinic compounds with amidine basic centers. A useful bioisosteric replacement of classical cationic heads.

Amidine moieties are effective bioisosteric substitutes for conventional cationic heads present in antimuscarinic agents, and their unusual physical-chemical properties make them useful tools when modulation of pharmacokinetic or pharmacodynamic effects is required.